Abstract: Many chemotherapeutic compounding units are confronted with the problem of product delivery to different care wards. We think that transport by a pharmacy agent does not permit appropriate traceability (wrong care service delivery), control of storage temperature and management of urgency. We have developed a delivery system based on the association of a pneumatic transport system (PTS) and monitored buffer storage area. Thus, after pharmaceutical inspection, chemotherapies are placed in specific and hermetic carriers in the PTS but not directly delivered to care units. In the monitored buffer storage, a robotic arm organizes chemotherapies and waits for the nurse call just before administration. This system permits a real traceability for each stage of the chemotherapy circuit and so, we are now able to certify that chemotherapeutics have been maintained at the correct temperature through continual monitoring. It's an important prerequisite in standardization and reassignment. Finally, an important issue linked to the use of PTS is the risk of damaging the chemotherapeutics. Data obtained from literature and manufacturers for antibodies highlight the low risk to use a PTS.
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Keywords: chemotherapeutics, pneumatic transport system, cytotoxic-drug handling, robotic arm, monitored buffer storage area Confronted with the problem of safe product delivery to different care wards, many chemotherapeutic compounding units require a full-time employee who is responsible for delivering the correct drug to the appropriate care service while ensuring that they are quickly supplied and correctly stored. This method of transport does not permit appropriate traceability and unfortunately, chemotherapy bags could be delivered to the wrong care service. This can lead to a waste of time for patients and medical staff. Moreover, proper storage cannot be guaranteed; thus, chemotherapy bags are occasionally improperly stored. As a result, these chemotherapies are unusable. With this kind of transport, chemotherapy shipments are not always in balance with the care unit needs and priorities. So, nurses do not always have the required time to ensure chemotherapy reception. Finally, the management of urgent chemotherapies is difficult because it depends on the availability of the courier.
In order to solve these problems, we have acquired a pneumatic transport system (PTS). The use of a PTS is not recommended in the literature [1, 2] for the transportation of cytotoxic drugs because of the risks of contamination (bag leak in the system) and cross-contamination (due to the presence of multiple medications, biologic samples or materials).
In our case, we use specific carriers designed for chemotherapy transport Figure 1 . These carriers are rigid, hermetic and resistant to a maximum of 1 bar pressure, which not only protects the chemotherapy bags against impacts occurring during transport but also contains potential product leaks due to damage. Additionally, each carrier contains only one chemotherapy bag, which is wrapped before it is placed inside the carrier. The main objective of these means is to protect the entire pneumatic network against contamination. Finally, in our center, the pneumatic system is reserved only for the transport of chemotherapy bags.
However, we considered that the use of a simple PTS is not sufficient to ensure traceability, a proper storage chain or flow management. Thus, after pharmaceutical inspection, chemotherapies are placed in the PTS but not directly delivered to care units. We have developed two monitored buffer storage area located between the compounding unit and the care service, one at + 25°C and one at + 5°C (Figure 2 ), where carriers are placed by a robotic arm and await to be called by the nurses just before administration. In these two storage zones, 10 racks containing 16 cases, for a total of 160 spaces, enable us to stock our entire supply without difficulty. With this system, the nurses no longer depend on human intervention and bags are delivered on request. The management of urgent chemotherapies is possible because bags are immediately available after being kept in the storage area.
Moreover, nurses are free to manage the bag's call according to the patient's needs. The carriers are sent within a minute from the storage zone to the care service for administration.
For one special care ward, the day care center, which has an uninterrupted activity all day long, chemotherapies stored at room temperature (and whose administration is expected on the very day) are sent directly in the care ward for their immediate use. However, bags that must be kept at a low temperature, or stored at room temperature but for another day, are still sent from the buffer storage area to preserve the temperature traceability.
The nurses have full access to all functionalities related to the chemotherapy request with their usual patient care plan software. Thus, the entire project's viability depends on our ability to interface the PTS software with our prescription, preparation, dispensation and administration software. We collaborated with both software companies to develop specific software versions that permit communication of the following data: patient's name and date of birth, care service, cytotoxic agent, dose, date of administration, and storage conditions. All of these data are registered in a barcode on the bag's label, which enables the PTS to assign the chemotherapy to the correct patient in the right care service and to send bags either in the cooled storage or in ambient temperature, according to their recommended storage conditions. To reduce the patient waiting period, chemotherapies are prepared as early as possible based on their stability. Every day, we send anticipated chemotherapies to the storage area, so the nurses have them at their disposal on the following days without any unnecessary delay. This practice permits a real time saving for all of the services and patients. The system eliminates incorrect delivery of therapeutics, which can disturb the nurses and lead to possible mistakes. Moreover, if the patient therapy is cancelled, storage conditions remain ensured because the carriers stay in the monitored buffer storage area. A two-way system allows the return of empty carriers from any care ward to the pharmacy unit. We can also receive carriers directly from the storage zone in case of therapy cancellation, thanks to a special function of the software, allowing us to avoid overloading the storage zone.
Finally, an important issue linked to the use of PTS is the risk of damaging the chemotherapeutics. Pneumatic transport is well described for biologic sample transport and, in this case, the literature highlights the risk of change, damage, haemolysis and activity loss [3] [4] [5] [6] .
In 2014, Randolph et al. [7] described a risk of cavitation, protein aggregation and particles formation after mechanical shocks in vials. This study deals with concentrated solutions in glass vials which is different to our purpose (plastic packaging and diluted solutions). They concluded that, even if the loss of monomeric protein was not large enough to affect potency of the protein, the subvisible particles have the potential to affect immunogenicity, besides the other clinical consequences [8] . So, as recommended, some anticancer drugs are being filtered with a 0.2 µm filter before their administration. This practice can protect the patient against the particles previously mentioned. Moreover, the health-professionals in the different care wards have been informed about the risks associated with the PTS and are instructed to be particularly attentive to any irregularity they can detect.
Moreover, in our case, for chemotherapy transport and especially for antibodies solution, the existing publications demonstrated a lack of risk for many antibodies. Thus, Bristol-Myers Squibb Drug Product Science and Technology Department has demonstrated a stability of nivolumab infusion bags during 24 hours with no difference between the shacked bag and the nonshacked control bag [9] . Vieillard et al. [10] [11] [12] have determined a comparable stability of rituximab, trastuzumab and cetuximab diluted in saline in polyolefin bags using orthogonal analytical methods according to the "Guidelines for the practical stability studies of anticancer drugs: A European consensus conference" [13] (size exclusion chromatography, dynamic light scattering, turbidity, infra-red spectroscopy). However, two conditions have to be controlled to ensure the stability: -Air-liquid interface, which is the risk-determining factor -Number of routes For that purpose, we have decreased the quantity of air and allowed a maximum volume of 5 mL (instead of 20 mL), which is needed to permit complete administration. Moreover, the use of monitored buffer storages area allows a control of routes: the chemotherapy will only take one path after being called in the services, which limits the time spent in the PTS and the stress put on the bags. Concerning the risk of foam formation due to excessive agitation from the PTS, we have insufficient data but for the moment there has not been any complaint since the launch of the PTS, unlike manual transport. We think that decreasing the air-liquid interface does reduce the risk.
Thus, in our cancer treatment center, we have decided to transport all chemotherapeutics (approximately 34,000 chemotherapeutics per year) using the PTS combined with the innovative automated storage areas. This kind of transport solves the issue of traceability, appropriate storage conditions and emergency management. It avoids a real waste of time for patients and medical staff as well as chemotherapy losses due to unusable units, which were wrongly stored. Thanks to color-coding, it indicates the state of each carrier from shipment with the PTS to reception in the different care services. So, we are able to rapidly determine the location of the carrier (still in the storage zone, on the way to the service or already received) in case a bag is missing. The software records the date and hour at which the bags were sent via the PTS and received at the services. With this system, we can certify that chemotherapeutics have been maintained at the correct temperature through continual monitoring. However, to exclude risks linked to the transport of monoclonal antibodies solutions, known mechanical stress parameters of our PTS (Average velocity: 3 to 4 m/s; Acceleration: 0.15 g; Deceleration: 3 g; Distance from 45 to 200 m) must be completed by jolts study and compared to human transport.
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